Press release
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising
About this update from Incyte Corporation
[{"type":"text","content":" WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin.\n\n\n“We are encouraged by the positive findings being presented with our TGFβR2×PD-1 and KRAS G12D inhibitor programs, which validate our rationale for advancing the development of these novel investigational compounds,\" said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. \"There remains a significant need for new treatment options for patients with advanced solid tumors like colorectal cancer and pancreatic ductal adenocarcinoma and we look forward to providing updates on these clinical development programs.”\n\n\nDetails on INCA33890 and INCB161734 oral presentations at ESMO include:\n\n\nINCA33890 (PD-1/TGFβR2)\n\n\nA Phase 1 Study Of INCA33890, A PD-1/TGFβR2 Bispecific Antibody, For Advanced Solid Tumours\n(Session Title: Mini oral session: Investigational immunotherapy. [October 17, 8:00 – 9:30 a.m. ET [2:00 – 3:30 p.m. CEST]. Abstract #1522.)\n\n\nINCB161734 (KRAS G12D)\n\n\nPreliminary Phase 1 Results Of INCB161734, A Novel Oral KRAS G12D Inhibitor, In Patients With Advanced Or Metastatic Solid Tumors\n(Session Title: Proffered paper session: Developmental therapeutics. [October 19, 8:45 – 10:20 a.m. ET [2:45 – 4:20 p.m. CEST]. Abstract #916O.)\n\n\nAnalyst Event and Webcast\nThe data from the ESMO oral presentations and additional results from the INCA33890 in patients with microsatellite stable (MSS) colorectal cancer and INCB161734 in pancreatic ductal adenocarcinoma (PDAC) will also be discussed at an in-person analyst and investor event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. ET (7:30 – 9:00 p.m. CEST) at ESMO.\n\n\nThe event will be webcasted and can be accessed via the Events and Presentations tab of the Investor section of Incyte.com and it will be available for replay for 30 days.\n\n\nMore information regarding the 2025 ESMO Congress can be found at: https://www.esmo.org/meeting-calendar/esmo-congress-2025.\n\n\nAbout Incyte\nA global biopharmaceutical company on a miss...